More than 8 million people go to the emergency room for chest pains every year. But 3 out 4 of the cases do not involve heart-related issues. Founded in 2017, Genetesis markets the  CardioFlux® medical imaging device to hospital emergency rooms that shows heart activity in a non-invasive manner. The imaging process takes 90 seconds and has the potential to provide more effective diagnosis of life-threatening conditions. CincyTech and Mark Cuban of Radical Investments led Genetesis' $7.5 million Series A round of financing, and CincyTech led the seed round of funding.

CardioFlux®, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA) for the diagnosis of myocardial ischemia and infarction in patients with symptoms of acute chest pain.